AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch

Research shows defense against infection fades by 15 weeks, but protection against serious illness may be longer, according to researchers at Sheba Medical Center

Sheba-led research team says that 6 months after boosters, 'antibody levels and cumulative vaccine efficacy do not differ between the two vaccines'

AION Labs, a Rehovot-based consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company that will help drug firms improve chances of success in clinical trials

US pharmaceutical giant to make $20m equity investment, part of larger agreement to license tech and collaborate on R&D

Second-generation vaccines being distributed to healthcare providers, as scientific community waits expectantly to see how much they help

Massachusetts-based firm accuses rival and its partner of copyright infringement, filing suit in both US and German courts

Albert Bourla insists his company's original vaccine is safe for children as young as 6 months, says he's aiming to create vaccine that offers yearlong protection

Pharma firm announces it has 'two very strong' candidates against the coronavirus variant, as US regulators set to weigh whether to offer updated boosters

CEO Albert Bourla says Paxlovid 'remains one of the best tools we have' to fight coronavirus, US pharma firm working to develop booster that provides immunity for a year